IGM Biosciences Company Insiders
| IGMS Stock | USD 10.04 0.39 3.74% |
Slightly above 67% of IGM Biosciences' corporate insiders are selling. The analysis of the overall insider sentiment regarding IGM Biosciences suggests that many insiders are alarmed. IGM Biosciences employs about 198 people. The company is managed by 18 executives with a total tenure of roughly 462 years, averaging almost 25.0 years of service per executive, having 11.0 employees per reported executive.
IGM Biosciences' Insider Buying Vs Selling
33
Selling | Buying |
Latest Trades
| 2024-09-13 | Fred Schwarzer | Disposed 3946 @ 11.54 | View | ||
| 2024-07-25 | Julie Hambleton | Disposed 15132 @ 14 | View | ||
| 2024-06-14 | Steven Weber | Disposed 495 @ 7.58 | View | ||
| 2024-03-28 | Bros. Advisors Lp Baker | Acquired 97473 @ 9.62 | View | ||
| 2024-03-26 | Bros. Advisors Lp Baker | Acquired 270000 @ 8.26 | View | ||
| 2024-03-13 | Misbah Tahir | Disposed 2897 @ 9.88 | View | ||
| 2023-12-15 | Bros. Advisors Lp Baker | Acquired 288007 @ 6.55 | View | ||
| 2023-12-13 | Fred Schwarzer | Disposed 17576 @ 5.78 | View | ||
| 2023-11-29 | Chris H Takimoto | Disposed 1180 @ 6.21 | View |
Monitoring IGM Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
IGM |
IGM Biosciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with IGM Biosciences' future performance. Based on our forecasts, it is anticipated that IGM will maintain a workforce of slightly above 200 employees by January 2025.IGM Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.3738) % which means that it has lost $0.3738 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3211) %, meaning that it created substantial loss on money invested by shareholders. IGM Biosciences' management efficiency ratios could be used to measure how well IGM Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to drop to -0.73 in 2024. At this time, IGM Biosciences' Other Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 10 M in 2024, whereas Total Assets are likely to drop slightly above 300.2 M in 2024.Common Stock Shares Outstanding is likely to drop to about 26.4 M in 2024. Net Loss is likely to gain to about (189 M) in 2024
IGM Biosciences Workforce Comparison
IGM Biosciences is rated fifth overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,503. IGM Biosciences holds roughly 198 in number of employees claiming about 8% of equities under Health Care industry.
IGM Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IGM Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on IGM Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, IGM Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 1.25 | 20 | 16 | 398,538 | 671,552 |
| 2024-06-01 | 0.9167 | 11 | 12 | 25,407 | 431,452 |
| 2024-03-01 | 2.7333 | 41 | 15 | 1,782,352 | 157,015 |
| 2023-12-01 | 2.2 | 22 | 10 | 569,789 | 37,601 |
| 2023-09-01 | 8.0 | 8 | 1 | 5,260 | 936.00 |
| 2023-06-01 | 3.4667 | 52 | 15 | 14,541,321 | 143,375 |
| 2023-03-01 | 1.4286 | 10 | 7 | 39,549 | 41,240 |
| 2022-12-01 | 0.4 | 14 | 35 | 648,077 | 1,188,526 |
| 2022-09-01 | 3.0 | 12 | 4 | 21,506 | 26,498 |
| 2022-06-01 | 3.1111 | 28 | 9 | 10,061,261 | 12,424 |
| 2022-03-01 | 21.5 | 43 | 2 | 4,220,929 | 7,800 |
| 2021-12-01 | 3.1429 | 22 | 7 | 87,588 | 10,300 |
| 2021-09-01 | 0.8571 | 12 | 14 | 160,796 | 20,100 |
| 2021-06-01 | 0.7308 | 19 | 26 | 15,452 | 128,600 |
| 2021-03-01 | 1.44 | 36 | 25 | 381,651 | 52,988 |
| 2020-12-01 | 1.9474 | 37 | 19 | 1,719,604 | 23,120 |
| 2020-09-01 | 2.6364 | 29 | 11 | 317,069 | 7,235 |
| 2020-06-01 | 3.0 | 15 | 5 | 50,300 | 43,429 |
| 2019-09-01 | 1.5517 | 45 | 29 | 78,627,031 | 74,605,039 |
IGM Biosciences Notable Stakeholders
An IGM Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as IGM Biosciences often face trade-offs trying to please all of them. IGM Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting IGM Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Fred JD | President CEO | Profile | |
| Mary MD | President Unit | Profile | |
| Steven Weber | Corporate VP | Profile | |
| TS Harigopal | Senior Operations | Profile | |
| Faraz Siddiqui | Senior Operations | Profile | |
| Angus Sinclair | Senior ImmunoOncology | Profile | |
| Elizabeth JD | Senior Property | Profile | |
| Elaine Sapinoso | Senior Quality | Profile | |
| Misbah CPA | Chief Officer | Profile | |
| Lisa Decker | Chief Officer | Profile | |
| Paul JD | Senior Affairs | Profile | |
| Shinyu MD | Consultant | Profile | |
| Bruce Keyt | Chief Officer | Profile | |
| Suzette Tauber | Chief Officer | Profile | |
| Misbah Tahir | Chief Officer | Profile | |
| Paul Graffagnino | Senior Affairs | Profile | |
| FACP MD | Chief Officer | Profile | |
| Marvin Peterson | Executive Manufacturing | Profile |
About IGM Biosciences Management Performance
The success or failure of an entity such as IGM Biosciences often depends on how effective the management is. IGM Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of IGM management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the IGM management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.69) | (0.73) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.21) | (1.15) |
Please note, the imprecision that can be found in IGM Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IGM Biosciences. Check IGM Biosciences' Beneish M Score to see the likelihood of IGM Biosciences' management manipulating its earnings.
IGM Biosciences Workforce Analysis
Traditionally, organizations such as IGM Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare IGM Biosciences within its industry.IGM Biosciences Manpower Efficiency
Return on IGM Biosciences Manpower
| Revenue Per Employee | 10.8K | |
| Revenue Per Executive | 118.3K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 13.7M | |
| Working Capital Per Employee | 1.5M | |
| Working Capital Per Executive | 17M |
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.